Abstract. The putative tumor suppressor gene WW domain containing oxidoreductase (WWOX) spans a common fragile site (CFS) on chromosome 16q23.3. CFSs are regions of profound genomic instability and sites for genomic deletions in cancer cells. Therefore, WWOX is structurally altered in diverse nonhematological cancer types. However, the function of WWOX in hematological tumor types, including multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) remains unclear. WWOX expression and methylation in patients with MM, MGUS, or noninvasive lymphoma (control) were analyzed using reverse transcription and methylation specific-polymerase chain reaction analysis. Variant WWOX transcripts were detected in 65 and 50% of patients with MM and MGUS, respectively, compared with 10% of controls. WWOX expression was higher in patients with MM, and WWOX promoter methylation was detected in 35% of patients with MM compared with 5% of patients with MGUS and 4% of controls. WWOX promoter methylation was significantly associated with shorter overall survival time of patients, in particular those with MM who were never treated with novel agents. Genomic alterations, including deletions and promoter methylation that affect WWOX expression occur early and may be involved in the pathogenesis, progression, and prognosis of MM.

Introduction

The underlying molecular mechanism of multiple myeloma (MM) is associated with oncogene activation caused by the translocation of the immunoglobulin heavy chain gene (1,2). Mutations or deletions of certain genes are also involved (3,4). Although MM is incurable, the median survival time is currently 5-7 years compared with 3 years before 2000 due to the development of novel therapies (5). The prognosis of patients with MM is associated with genetic abnormalities (3), and the identification of molecular genetic markers for predicting prognosis is therefore essential. The application of high-throughput next-generation sequencing techniques has contributed to efforts to understanding the pathogenesis of MM (3,4); however, full coverage of the genomic alterations involved remains unclear.

Chromosomal instability is a feature of certain cancer types and is associated with the presence of chromosomal fragile sites (CFSs) (6). Common fragile sites are present in normal chromosomes, and are prone to forming chromosomal gaps and breaks under conditions that partially inhibit DNA synthesis (7). Furthermore, CFSs are regions of profound genomic instability and are frequent sites for deletions and other alterations in cancer cells (8,9). Fragile site aphidicolin type common fragile site (16) (q23.2) (FRA16D) on chromosome 16q23.2 is the second most frequently expressed CFS region (10) and has been identified as deleted in multiple types of cancer (11-13).

The WW domain containing oxidoreductase (WWOX) gene was identified as a putative tumor suppressor gene (14-17) and spans FRA16D (16q18,19). Genomic alterations, including homozygous and hemizygous deletions that affect the WWOX locus, occur in certain types of cancer (20-22). Deletion of all or part of chromosome 16q and loss of heterozygosity

Correspondence to: Dr Hiroshi Handa, Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan
E-mail: handahiroshi@gunma-u.ac.jp

*Contributed equally

Key words: multiple myeloma, monoclonal gammopathy of undetermined significance, WW domain containing oxidoreductase gene, common fragile site, methylation
occurs in patients with MM (23-25). In addition, relatively low expression levels of WWOX and the cylindromatosis gene, which reside on chromosome 16q, have been associated with worse prognosis (24).

WWOX is the target of recurrent deletions of chromosome 16q (15-17,19) that disrupt one WWOX allele by removing exons 6-8 that encode the oxidoreductase domain, leading to the production of variant transcripts. WWOX variant transcripts are frequently identified in breast, lung, esophageal and hematological malignancies (17,26-30).

There is evidence to indicate that the loss of full length WWOX expression is due to the localization of WWOX at one of the most active human CFSs (15-17,19); however, other studies have demonstrated that the methylation of the WWOX promoter leads to decreased expression (31-33). Furthermore, epigenetic processes, particularly DNA methylation, are involved in carcinogenesis, and multiple studies have reported an association between the methylation of tumor suppressor genes and poor prognosis of patients with MM (34-40).

Genes with CFSs are often methylated in various types of malignancy (41,42), but little information is available regarding hematologic malignancy types (43,44). In addition, the methylation of the WWOX promoter has been associated with worse prognosis of patients with different types of cancer (31,45-47). To the best of our knowledge, no previous studies have reported an association between alterations of WWOX and progression of MM. The present study aimed to elucidate the function of WWOX in the pathogenesis of MM.

Materials and methods

Cell lines. The human myeloma cell line RPMI8226 was obtained from the American Type Culture Collection (Manassas, VA, USA), and KMS11, KMS12PE, KMM1, KMS18, and KMS26 human myeloma cell lines were provided by Dr Takemi Otsuki (Kawasaki Medical School, Okayama, Japan). The cell lines were cultured in 10 ml RPMI-1640 medium (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) supplemented with 10% fetal bovine serum (Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37°C in an atmosphere containing 5% CO2.

Patients. Subjects included 165 patients with MM (82 male and 83 female) and an average age of 67 (range 34-87), 33 patients (16 male and 17 female) with monoclonal gammapathy of undetermined significance (MGUS) with an average age of 67 (range 44-81), diagnosed according to International Myeloma Working Group (IMWG) Criteria for the Diagnosis of Multiple Myeloma (48) and 25 patients with lymphoma lacking infiltration of the bone marrow as a control. All patients were treated at Gunma University Hospital between January 2004 and September 2011. The present study was approved by the Institutional Review Board of Gunma University Hospital (IRB no. 810). Written informed consent was obtained from all patients prior to 3 ml of bone marrow aspirate collection.

Plasma cell purification. The plasma cells were purified from BM mononuclear cells from 30 MM patients using anti-CD138 antibody conjugated with PE (Beckman-Coulter, Brea, CA) and Easy Sep PE positive selection containing anti-PE antibody conjugated with micro-magnetic beads kit (STEMCELL Technologies, Vancouver, BC, Canada). The purity of the CD138 positive plasma cells was analyzed using a flow cytometer (FACSCanto II, Becton Dickinson, San Jose, CA, USA).

Isolation of nucleic acids. DNA was extracted from 88 patients with MM using QIAamp DNA Blood Midi kit (Qiagen, Inc., Valencia, CA, USA), according to the manufacturer's protocol. DNA and RNA were extracted from 77 patients with MM and 33 patients with MGUS and 25 patients with lymphoma lacking infiltration of the bone marrow, respectively, using an All-Prep mini-kit (Qiagen, Inc.) according to the manufacturer's protocol.

Nested reverse transcription-polymerase chain reaction (RT-PCR) analysis of WWOX transcripts. cDNA was synthesized from 10 ng total RNA obtained from 77 patients with MM, 33 patients with MGUS and 25 control patients, and cell lines KMM1, KMS11, KMS12PE, KMS18, KMS26 and RPMI8226 using a PrimeScript RT-PCR kit with gDNA Eraser (Takara Bio, Inc., Otsu, Japan). The first and second PCR amplifications were performed using the nested primers as follows: First forward, 5'-AGTTTCTCTAGCGGAGTGA CC-3' and reverse, 5'-TACTTTCTACAAGGCAACCAC-3' and second forward, 5'-AGGTGCTTCCACAGTC-3' and reverse, 5'-GTGTGTGCCCATGCCCTG3' (29,30). Each reaction (50 µl each) contained 0.2 µmol of each primer, 2.0 mM MgCl2, 0.2 mM dNTP mix, 1X PCR buffer and 1.25 units of Takara ExTaq Hot Start Version (Takara Bio, Inc.). The thermocycling conditions maintained were as follows: 95°C for 8 min; 35 cycles at 94°C for 30 sec, 57°C for 30 sec, and 72°C for 1 min; and an extension step at 72°C for 5 min. A total of 1 µl amplification product from the first reaction was used for the second reaction. The amplicons were electrophoresed through a 2% agarose gel and visualized using ethidium bromide.

Methylation-specific PCR (MSP). The CpG island of the WWOX gene is located 406 bp upstream of the transcription start site and is considered the promoter region. MSP was used to detect the methylation levels of this region. DNA obtained from 165 patients with MM, 33 patients with MGUS and 25 control patients, and cell lines KMM1, KMS11, KMS12PE, KMS18, KMS26 and RPMI8226 were used for the MSP analysis. Each 0.5 µg sample of genomic DNA was treated with sodium bisulfite using the MethylEasy Xceed Rapid DNA Bisulfite Modification kit (Takara Bio, Inc.) following manufacturer's protocol, and the converted DNA was subjected to PCR. MSP was performed using specific primers designed to amplify methylated or unmethylated sequences of the WWOX promoter. The primer sequences for methylated or unmethylated DNA are as follows: Methylated forward, 5'-TATGGGG CGTCGTTTTTTAGTT-3' and reverse, 5'-CAATCTCCG CAATATCCGCACA-3'; unmethylated forward, 5'-TATGGGTGTGGTTTATAGTT-3' and reverse, 5'-CAATCTCCACATATCACAACA-3' (31). Each reaction (20 µl each) contained 0.2 µmol of each primer, 2.0 mM MgCl2, 0.2 mM dNTP mix, 1X PCR buffer and 1.25 units of Takara ExTaq Hot Start Version (Takara Bio, Inc.). The thermocycling conditions
maintained were as follows: 95°C for 8 min; 35 cycles at 94°C for 30 sec, 58°C for 30 sec, and 72°C for 1 min; and an extension step of 72°C for 5 min. The amplicons were electrophoresed through a 2% agarose gel and visualized using ethidium bromide.

**Statistical analysis.** IBM SPSS software (version 22.0; IBM SPSS, Armonk, NY, USA) was used for statistical analysis. Frequencies were compared using the χ2 test, and mean values were compared using the Student’s t-test or the Mann-Whitney U test. Overall survival (OS) and statistical significance were calculated using the Kaplan-Meier estimator method, log-rank test, and generalized Wilcoxon test.

**Results**

**Analysis of WWOX mRNAs.** Nested PCR assays (Fig. 1A) detected the full-length wild-type WWOX mRNA and a short variant WWOX mRNA lacking exons 6-8. The variant type was expressed at low levels by KMM1 and KMS18 cells, and at higher levels by KMS11 and RPMI8226 cells. Full-length wild-type WWOX was detected in KMS12PE and KMS26 cells, and RPMI8226 cells expressed the wild-type and variant transcripts.

WWOX transcripts were undetectable in 9 patients with MM, 7 patients with MGUS and 4 patients with lymphoma (data not shown), and those patients were excluded from the following analysis. The variant WWOX mRNA was detected in 44/68 (65%) patients with MM (Fig. 1B), 13/26 (50%) cases of patients with MGUS and in 2/21 (10%) patients with lymphoma (Table I). This indicated that MM and MGUS bone marrow cells expressed the variant WWOX at a similar frequency (P=0.16), and at a significantly higher frequency compared with lymphoma bone marrow cells (P<0.001 and P=0.004, respectively; Table I). The similar high frequencies of detection of variant WWOX mRNA in patients with MM and MGUS suggested that WWOX alteration occurred during the premalignant stage of MM.

CD138-positive plasma cells and CD138-negative bone marrow cells obtained from the same patients with MM were purified and analyzed to determine whether variant WWOX was expressed by plasma cells. The variant WWOX mRNA was detected in the CD138-positive plasma cells of 17/30 patients (57%), which was equivalent to the results of the analysis of whole-marrow mononuclear cells of patients with MM described above (P=0.45; data not shown). This was significantly higher compared with the detection in 6/30 (24%) of the CD138-negative cell samples (P=0.01). These results indicated that the variant form of WWOX mRNA was a genuine abnormality of MM cells and not a characteristic of all hematopoietic cells.

**Methylation of the WWOX promoter in MM cell lines and tumor cells.** MSP analysis detected WWOX promoter methylation in 2/6 (KMM1 and KMS18) cell lines (Fig. 2A) and in 3/4 patients with MM (Fig. 2B). Methylation of the WWOX promoter was detected in samples from 18/65 (35%) patients with MM, 2/33 (6%) patients with MGUS, and in 1/25 patients with lymphoma (4%). The frequency of WWOX promoter methylation in patients with MM was significantly higher compared with those with MGUS (P=0.001) or lymphoma (P=0.002), but the difference was not significant between patients with MGUS or lymphoma (P=0.73; Table I). This indicated that WWOX was preferentially methylated in MM cells.

To determine whether methylation was specific for WWOX or reflected the methylation status of tumor suppressor genes in MM cells, Ras association domain family member 1 isoform A (RASSF1A) promoter methylation was detected in the DNA of the KMM1 and KMS18 cell lines. (B) Methylated and unmethylated WWOX promoter DNA of patients with MM was detected. WWOX, WW domain containing oxidoreductase; bp, base pairs; MM, multiple myeloma.
suggesting that specific methylation of WWOX was associated with the progression of MM.

**Association between the prognosis of patients with MM and WWOX promoter methylation.** The association between WWOX promoter methylation and the OS of patients with MM was determined using the Kaplan-Meier estimator method, log-rank, and the generalized Wilcoxon test. The median OS time was shorter in patients with methylated WWOX sequences compared with those without methylation (3.83 vs. 6.29 years, respectively). As novel agents, namely bortezomib, thalidomide, and lenalidomide, are effective for treating MM, the patients were stratified according to those treated with or without novel agents and the data were analyzed again. The median OS time of patients with WWOX promoter methylation was shorter compared with those without methylation (2.1 vs. 6.3 years). The difference was significant according to the results of the generalized Wilcoxon test (P=0.04) and the log-rank test (P=0.02; Fig. 3B). In contrast, no significant difference between the median OS times of each class of patients treated with novel agents were identified (methylation, 5.1 years; undetectable methylation, 5.4 years; P=0.73; data not shown).

**Analysis of WWOX promoter methylation, β2-microglobulin levels, and International Staging System (ISS) classification.** The higher incidence of WWOX promoter methylation in patients with MM compared with those with MGUS, and
the association between methylation and shorter OS time, indicated that WWOX promoter methylation was associated with disease progression. To support this hypothesis, the association between WWOX promoter methylation, serum β2-microglobulin levels and MM stage was analyzed according to the ISS (49). The mean β2-microglobulin level was significantly higher in patients with WWOX promoter methylation compared with those without (6.80 vs. 4.68 mg/l; P=0.02; data not shown). The frequency of patients at ISS stage 3 with WWOX promoter methylation was significantly higher compared with those without methylation (P=0.02; data not shown).

Discussion

In the present study, recurrent expression of a short form of WWOX mRNA was demonstrated in patients with MM or MGUS. Furthermore, it was revealed that the WWOX promoter was frequently methylated in patients with MM, and that this increased during the progression of disease from MGUS to advanced MM. In addition, WWOX promoter methylation was identified to be associated with a shorter median OS time.

The wild-type transcript is ubiquitously expressed and shorter variants also occur (15,17). For example, homozygous deletion of chromosome 16q23.2 in various cancer cell lines includes deletions of WWOX exons (17) that generate shorter WWOX mRNA variants. In a previous study, numerous truncated WWOX variants lacking exons 5–8 were identified in clinical samples obtained from patients with breast cancer (27). Reduced expression of the full-length WWOX transcript by cancer cells and the detection of high levels of variant WWOX transcripts that occur specifically in tumors indicates that WWOX may be involved in oncogenesis (27).

In the present study, variant WWOX mRNAs were detected in myeloma cell lines and plasma cells of patients with MM or MGUS, but at a significantly lower frequency in the cells of control patients. These results indicated that WWOX alteration was associated with aberrant plasma cells.

The instability of CFSs correlates with genomic instability in precancerous lesions (50) and the early stages of oncogenesis are associated with the DNA damage response (50,51). Genomic instability and abnormalities are hallmarks of MM, and aberrant DNA repair pathways are involved in disease onset and progression (52). WWOX deficiency reduces the levels of ATM serine/threonine kinase and impairs DNA repair, which may drive genomic instability (51). Therefore, WWOX alterations may also cause genomic instability. The results of the present study on variant WWOX mRNA expression in patients with MGUS suggested that the alteration of a CFS indicates genomic instability at an early stage of the disease.

Studies of WWOX protein knockout and hypomorphic mice have demonstrated that a functional defect of WWOX leads to the induction of various types of tumor, including lymphoma and plasmacytoma (53-55). In vitro, WWOX inhibits β-catenin (56) and suppresses the transcriptional activity of the nuclear factor-xB (NF-xB)-RELA proto-oncogene, NF-xB subunit complex (57), which are involved in the pathogenesis of MM. Variant WWOX serves as a dominant-negative factor in vitro to inhibit the tumor suppressor function of wild-type WWOX (26). These findings, taken together with those of the present study, support the hypothesis that the loss of WWOX function serves a causative role in the pathogenesis of MM.

The frequent detection of WWOX promoter methylation in the cells of patients with MM, in contrast to patients with MGUS and the control group, indicates that WWOX promoter methylation is associated with MM progression. This is consistent with findings that WWOX methylation correlates with poor prognosis of patients with ovarian cancer (47), head and neck cancer (58), and choriocarcinoma (59).

No significant correlation was identified between WWOX methylation and OS. This result may be due to improved treatment outcomes using novel agents. Therefore, patients were stratified according to the types of therapy they received and prognosis was identified as being worse for patients with WWOX methylation if they had not received treatment with a novel agent, suggesting that WWOX methylation may be associated with resistance to conventional cytotoxic drugs.

In conclusion, the present study demonstrated that WWOX promoter methylation is associated with β2-microglobulin levels and ISS, indicating that WWOX methylation contributes to MM progression. Unlike WWOX, the rate of methylated RASSFIA was similar between patients with MGUS and MM. Therefore, the association of WWOX methylation with a more progressive and worse phenotype may not reflect the methylation of tumor suppressor genes.

Genomic instability is a hallmark of the majority of types of cancer, and is potentially involved in oncogenesis and the response to therapy. As WWOX is a putative human tumor suppressor gene, it appears possible that the selection for loss of function driven by fragile site instability is involved in MM progression. Further mechanistic studies are required to determine the role of WWOX and other genes within other CFSs in the pathogenesis of MM.

Acknowledgements

The present study was supported by the Ministry of Education, Science and Culture, Japan (grant no. 20590556).

References


